Cetera Investment Advisers
GALT icon

Cetera Investment Advisers’s Galectin Therapeutics GALT Stock Holding History

Cetera Investment Advisers’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$46.4K Sell
10,000
-4,220
-30% -$10.9K ﹤0.01% 4780
2026
Q1 		$39.7K Hold
14,220
– – ﹤0.01% 4606
2025
Q4 		$59.2K Buy
+14,220
New +$74.9K ﹤0.01% 4485

Other funds holding GALT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Cetera Investment Advisers's GALT Position: Q2 2026 in Review

Cetera Investment Advisers reduced its Galectin Therapeutics (GALT) stake by 30% in Q2 2026, selling an estimated $10.9K and leaving 10,000 shares worth $46.4K. The position accounts for ﹤0.01% of the portfolio, ranked #4780.

Cetera Investment Advisers first reported a position in GALT in Q4 2025 and has held it in 3 quarters since. The position peaked at $59.2K in Q4 2025. 98 funds tracked by Wall St. Rank hold GALT as of Q2 2026.

  • Cetera Investment Advisers held 10,000 shares of Galectin Therapeutics worth $46.4K as of Q2 2026.
  • Cetera Investment Advisers sold 4,220 Galectin Therapeutics shares in Q2 2026, an estimated $10.9K.
  • Galectin Therapeutics made up ﹤0.01% of Cetera Investment Advisers's portfolio in Q2 2026, its #4780 holding.
  • Cetera Investment Advisers first reported a position in Galectin Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Cetera Investment Advisers's Galectin Therapeutics position peaked at $59.2K in Q4 2025.
  • 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.

Based on Cetera Investment Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.